Incomplete IgG response to HIV-1 proteins and low avidity levels in recently converted HIV patients treated with early antiretroviral therapy

International Journal of Infectious Diseases

Volumn 14, Issue 11, 2010, Pages

  Re, Maria Carla ^a   Schiavone, Pasqua ^a   Bon, Isabella ^a   Vitone, Francesca ^a   De Crignis, Elisa ^a   Biagetti, Carlo ^a   Gibellini, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antibody avidity; HAART; Primary HIV 1 infection; Western blot

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN GP 120; IMMUNOGLOBULIN G; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS PROTEIN;

ADULT; ANTIGEN BINDING; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; MALE; SEROCONVERSION; VIRUS LOAD; WESTERN BLOTTING;

ADULT; ANTIBODY AFFINITY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; FEMALE; FOLLOW-UP STUDIES; GENE PRODUCTS, GAG; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNOGLOBULIN G; LONGITUDINAL STUDIES; MALE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RETROSPECTIVE STUDIES; RNA, VIRAL; VIRUS REPLICATION;

EID: 78149466554     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.06.015     Document Type: Article

References (26)

1. Kassutto S., Rosenberg E.S. Primary HIV type 1 infection. Clin Infect Dis 2004, 38:1447-1453.
2. Iweala O.I. HIV diagnostic tests: an overview. Contraception 2004, 70:141-147.
3. Hecht F.M., Busch M.P., Rawal B., Webb M., Rosenberg E., Swanson M., et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 16:1119-1129.
4. McFarland W., Busch M.P., Kellogg T.A., Rawal B.D., Satten G.A., Katz M.H., et al. Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J Acquir Immune Defic Syndr 1999, 22:484-489.
5. Suligoi B., Massi M., Galli C., Sciandra M., Di Sora F., Pezzotti P., et al. Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J Acquir Immune Defic Syndr 2003, 32:424-428.
6. Chawla A., Murphy G., Donnelly C., Booth C.L., Johnson M., Parry J.V., et al. Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J Clin Microbiol 2007, 45:415-420.
7. Lazzarotto T., Galli C., Pulvirenti R., Rescaldani R., Vezzo R., La Gioia A., et al. Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay. Clin Diagn Lab Immunol 2001, 8:196-198.
8. Mubareka S., Richards H., Gray M., Tipples G.A. Evaluation of commercial rubella immunoglobulin G avidity assays. J Clin Microbiol 2007, 45:231-233.
9. Sickinger E., Braun H.B., Praast G., Stieler M., Gundlach C., Birkenbach C., et al. Evaluation of the Abbott ARCHITECT Toxo IgM assay. Diagn Microbiol Infect Dis 2009, 64:275-282.
10. Lacabaratz-Porret C., Urrutia A., Doisne J.M., Goujard C., Deveau C., Dalod M., et al. Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection. J Infect Dis 2003, 187:748-757.
11. Altfeld M., Rosenberg E.S., Shankarappa R., Mukherjee J.S., Hecht F.M., Eldridge R.L., et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001, 193:169-180.
12. Smith D., Berrey M.M., Robertson M., Mehrotra D., Markowitz M., Perrin L., et al. Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection. J Infect Dis 2000, 182:950-954.
13. Roca B. Adverse drug reactions to antiretroviral medication. Front Biosci 2009, 14:1785-1792.
14. Gupta R.K., Hill A., Sawyer A.W., Cozzi-Lepri A., von Wyl V., Yerly S., et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9:409-417.
15. Adalid-Peralta L., Grangeot-Keros L., Rudent A., Ngo-Giang-Huong N., Krzysiek R., Goujard C., et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med 2006, 7:514-519.
16. Coyne K.M., Parry J.V., Atkins M., Pozniak A., McOwan A. Spontaneous HIV-1 seroreversion in an adult male. Sex Transm Dis 2007, 34:627-630.
17. Kassutto S., Johnston M.N., Rosenberg E.S. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy. Clin Infect Dis 2005, 40:868-873.
18. Amor A., Toro C., Jiménez V., Simón A., Ramos B., Soriano V. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 2006, 20:1460-1462.
19. Selleri M., Orchi N., Zaniratti M.S., Bellagamba R., Corpolongo A., Angeletti C., et al. Effective highly active antiretroviral therapy in patients with primary HIV-1 infection prevents the evolution of the avidity of HIV-1-specific antibodies. J Acquir Immune Defic Syndr 2007, 46:145-150.
20. Murphy G., Parry J.V. Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill 2008, 13. pii:18966.
21. Suligoi B., Galli C., Massi M., Di Sora F., Sciandra M., Pezzotti P., et al. Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J Clin Microbiol 2002, 40:4015-4020.
22. Re M.C., Schiavone P., Vitone F., Bon I., De Crignis E., Biagetti C., et al. Low avidity antibody: a reliable method to diagnose a recent HIV-1 infection. New Microbiol 2008, 31:19-26.
23. Adalid-Peralta L., Godot V., Colin C., Krzysiek R., Tran T., Poignard P., et al. Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection. J Leukoc Biol 2008, 83:1060-1067.
24. Hare C.B., Pappalardo B.L., Busch M.P., Karlsson A.C., Phelps B.H., Alexander S.S., et al. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection. Clin Infect Dis 2006, 42:700-708.
25. Markowitz M., Vesanen M., Tenner-Racz K., Cao Y., Binley J.M., Talal A., et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179:527-537.
26. Franklin A., Blanden R.V. Potential inhibition of somatic hypermutation by nucleoside analogues. Mol Immunol 2007, 44:666-669.